LPGO — Lipigon Pharmaceuticals AB Balance Sheet
0.000.00%
- SEK32.87m
- SEK8.87m
- SEK32.81m
Annual balance sheet for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.49 | 12.6 | 28.5 | 9.64 | 31.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.479 | 1.03 | 0.589 | 0.969 | 1.25 |
Prepaid Expenses | |||||
Total Current Assets | 3.21 | 15.2 | 29.3 | 10.7 | 33.6 |
Other Long Term Assets | |||||
Total Assets | 3.21 | 15.2 | 29.4 | 10.8 | 33.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.04 | 2.26 | 6.47 | 6.95 | 5.16 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.04 | 2.26 | 6.47 | 6.95 | 5.16 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 2.17 | 13 | 23 | 3.87 | 28.4 |
Total Liabilities & Shareholders' Equity | 3.21 | 15.2 | 29.4 | 10.8 | 33.6 |
Total Common Shares Outstanding |